A look at the problems men face in their lives, including the many men who have no money, no support and no help.

Men’s health products can’t save themThe men’s drug industry has been flooded with new products and has yet to develop a cure for prostate cancer, but it is working on a way to deliver a lifesaving solution.

According to a recent study, men have less life expectancy than women, are twice as likely to be unemployed and twice as prone to heart disease and diabetes, and are twice more likely to have a stroke.

The mens health product market is worth $8 billion (US$7.8 billion) and has become the second largest in the world behind the men’s pharmaceutical industry, which produces more than $20 billion (S$25 billion) worth of drugs annually.

But the market for men’s medicines is small, with a market share of just 10 per cent.

The only reason that men’s pills have been able to survive for so long is because of their strong popularity with young men, says Dr John Fauci, a professor of medicine at the University of Sydney and one of the study’s authors.

“They’re very good for a very young group of young men,” he says.

“We have a very strong connection with young males, we’ve done quite a bit of work with young boys and they really like them.”

Men’s medicines are very safeBut the safety of the products is not the only issue.

Men who take them suffer an array of side effects.

One of the most serious is the death of a healthy, young man.

Men are over-represented in suicidesIt’s a growing problem that men are overrepresented in suicide, and the main cause of death for men is heart disease.

But it’s not the main reason for death for the elderly and young.

According the Australian Bureau of Statistics, men are more likely than women to commit suicide.

It’s a cause of around 13 per cent of all suicides in Australia, but only about 4 per cent for people aged 65 and over.

The suicide rate for men in Australia is much higher than for women, but the disparity is even greater for those aged 60 to 74.

Men can get prostate cancerThe risk of prostate cancer increases with age, but when it does, the most common treatment is surgery.

According to the Australian Paediatric Society, surgery for men will increase the risk of a cancer by between 18 and 36 per cent, depending on the age of the patient.

But there are other options, too.

There are more than 3,000 men’s cancer therapies available and the National Cancer Council says it is one of only two cancer therapies that can help prevent men from developing the disease.

But these treatments are not all equal.

A new study from the University and Melbourne University found that men who take an experimental cancer drug called arsperidone are about 10 per oncogenic per cent less likely to develop prostate cancer than men who do not take the drug.

The study is published in the journal The Lancet.

But arsporidone may be worth itSome of the research suggests that men might benefit from using an experimental drug called clomiphene citrate.

It is the first compound ever approved for use in treating prostate cancer and was approved in July by the US Food and Drug Administration.

The drug works by inhibiting the enzyme that causes the prostate to break down into many more cells.

It works by blocking that enzyme, preventing the cancer from growing, and, crucially, it blocks the process that causes it to break into these new cells.

But it can also help to slow down the growth of prostate tumors and stop the cancer spreading.

There are two main groups of patients who benefit from this drug.

Those who have not yet been diagnosed with prostate cancer are given an injection of the compound and those who have prostate cancer have been given clomophene citate.

In this trial, patients who received the drug had no side effects at all.

However, they also showed improved prostate-specific antigen (PSA) levels, which are a sign of the presence of cancer cells.

Clomopene citrate has been approved by the Food and Drugs Administration for use to treat men with advanced prostate cancer who have lost more than 50 per cent or more of their hair.

But many men in the trial developed a reaction to the drug, which can be quite painful, and many developed symptoms that included severe pain, redness and swelling in their groin, armpits and back.

In the US, a study of a treatment called cyclophosphamide, which is being tested for its potential to treat prostate cancer in men with mild to moderate symptoms, showed it can help reduce pain and swelling, but its efficacy in treating symptoms is limited.

In addition, some men in this trial developed skin lesions in their eyes, which may have been caused by the